Immunological effects of COVİD-19 vaccines in experimental breast cancer model

One of suggested choices for controlling the COVID-19 outbreak is vaccination. Cancer patients have a higher risk of dying from COVID-19 than ordinary people, so they should be considered a high-priority group for vaccination. The aim of this study is to examine the effects of COVID-19 vaccines on breast cancer. For this purpose, 4T1 breast cancer BALB/c mouse model groups were performed. Two doses of Sinovac- CoronaVac (SV), Pfizer-BioNTech (B) vaccines, and Serum Physiological (SF) were applied to the groups at certain times. Weight and tumor size were monitored. Blood was taken on certain days, and 2019–nCov protein levels were measured and sacrificed on the 22nd day. The tumor, lymph nodes, and lungs were removed. Lung, half of the tumor tissues and lymph nodes Flow Cytometry analysis examined the levels of CD3+, CD4+, CD8+, CD62L+, CD11b+, Gr1+, and F4/80+ molecules. Regarding metastasis and necrosis rate, the other half of the lung and tumor tissues were investigated. No significant difference was observed in animal weight, tumor size, necrosis rate, lung metastasis, and tumor-infiltrating myeloid series cell rates. In the ELISA test, Sinovac-CoronaVac created sufficient antibodies in the first dose of the second Pfizer-BioNTech. The CD3+ rate in the lymph nodes was evaluated as high in the control group, and no significant difference was observed in the CD4+ and CD8+ rates. Although the myeloid cell rate was found to be higher in the vaccinated group than in the control group, no significant difference was observed compared to the SF group. No significant difference was observed in tumor size, lung metastasis, and immune parameters in the groups receiving COVID-19 vaccines compared to the control and SF groups. Key Words: Sinovac- CoronaVac, Pfizer-BioNTech, TNBC, BALB/c